Skip to main content

Infant Dextrose

Generic: Dextrose

Verified·Apr 23, 2026
NDC
0404-9844
RxCUI
727518
Route
INTRAVENOUS
ICD-10 indication
P70.3

Affordability Check

How much will you actually pay for Infant Dextrose?

In 30 seconds, see every legitimate way to afford Infant Dextrose — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About Infant Dextrose

What is this medication? Infant dextrose is a sterile solution of glucose in water specifically formulated for administration to newborns and young children. It is primarily used to treat neonatal hypoglycemia, a condition where a baby has dangerously low blood sugar levels. Because infants have limited energy stores and a high demand for glucose to support brain function and metabolic processes, this medication provides an immediate source of energy to stabilize their condition and prevent potential complications. In addition to treating low blood sugar, infant dextrose is often used as a source of calories and hydration for babies who are unable to feed orally or require supplemental nutrition during illness or recovery. It is typically administered through an intravenous line in a clinical setting, such as a neonatal intensive care unit, where the infant can be closely observed. Healthcare providers monitor blood glucose levels and adjust the concentration of the solution to ensure the baby receives the precise amount of energy needed for their specific medical requirements.

Copay & patient assistance

  • Patient Copay Amount: Not Publicly Available
  • Maximum Annual Benefit Limit: Not Publicly Available
  • Core Eligibility Restrictions: Not Publicly Available
  • RxBIN, PCN, and Group numbers: Not Publicly Available

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Prescribing information

From the FDA-approved label for Infant Dextrose. Official source: DailyMed (NLM) · Label effective Oct 27, 2025

Indications and usage
Indications and Usage 25% Dextrose Injection is indicated in the treatment of acute symptomatic episodes of hypoglycemia in the neonate or older infant to restore depressed blood glucose levels and control symptoms. Other drugs, such as epinephrine and glucagon, should be considered in patients unresponsive or intolerant to dextrose (glucose). Oral feeding of dextrose may be necessary in infants with frequently recurring hypoglycemic episodes or to prevent recurrences due to hyperinsulinemia. 25% Dextrose Injection also provides a minimal source of carbohydrate calories.
Dosage and administration
Dosage and Administration When possible, glucose concentrations of greater than 12% should be administered by central vein to reduce the risk for phlebitis and thrombosis. 25% Dextrose Injection, USP is administered only by slow intravenous injection. The dosage and constant infusion rate of intravenous dextrose must be selected with caution, particularly in neonates and low birth weight infants, because of the increased risk of hyperglycemia/ hypoglycemia. In the neonate, an injection of 250 to 500 mg (1 to 2 mL)/kg/dose (5 to 10 mL of 25% dextrose in a 5 kg infant) is recommended to control acute symptomatic hypoglycemia (tremors, convulsions,etc.). Larger or repeated single doses (up to 10 or 12 mL of 25% dextrose) may be required in severe cases or older infants. A specimen for blood glucose determination should be taken before injecting the dextrose. In such emergencies, dextrose should be administered promptly without awaiting pretreatment test results. Subsequent continuous intravenous infusion of 10% dextrose injection may be needed to stabilize blood glucose levels. Further treatment should be guided by evaluation of the underlying disorder. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS.
Contraindications
Contraindications A concentrated dextrose solution should not be used when intracranial or intraspinal hemorrhage is present.
Warnings
Warnings 25% Dextrose Injection, USP is hypertonic and may cause phlebitis and thrombosis at the site of injection. Significant hyperglycemia and possible hyperosmolar syndrome may result from too rapid administration. The physician should be aware of the symptoms of hyperosmolar syndrome, such as loss of consciousness.
Adverse reactions
Adverse Reactions Hyperosmolar syndrome, resulting from excessively rapid administration of concentrated dextrose may cause mental confusion and/or loss of consciousness. Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection and extravasation. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.

Label text is reproduced as-is from the FDA-approved label. We do not paraphrase, summarize, or omit. Content above is for informational purposes only and is not medical advice. Always consult your prescribing clinician or pharmacist before making decisions about your medication.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Prior authorization & coverage

PayerPAStep therapyCopay tier

Medicare Part D

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.